GlobalData survey finds that nearly half of pharma professionals expect R&D to benefit the most from digital technologies.

A recent survey of pharmaceutical professionals conducted by GlobalData reveals that nearly half of respondents expect digital technologies to benefit R&D efforts more than other activities. Artificial intelligence (AI) and big data are expected to have the biggest impact with respect to improving the productivity and effectiveness of R&D.

While there has not yet been a drug to reach the market that was identified using AI, the technology is being applied in the fields of diagnostics and radiotherapy, and significant investments are being made in the development of AI solutions for drug discovery and development. One challenge identified by the survey was the need for coordination within organizations with respect to identifying targets for digital transformation.